Literature DB >> 18221197

An update on GABA analogs for CNS drug discovery.

Perumal Yogeeswari1, Jegadeesan Vaigunda Ragavendran, Dharmarajan Sriram.   

Abstract

GABA (gamma-aminobutyric acid) is one of the major inhibitory transmitters in the central nervous system of mammals. GABA is not transported efficiently into the brain from the bloodstream (i.e. GABA does not effectively cross the blood-brain barrier). Consequently, brain cells provide virtually all of the GABA found in the brain i.e. GABA is biosynthesized by decarboxylation of glutamic acid with pyridoxal phosphate. The implication of low GABA levels in a number of common CNS disease states and/or common medical disorders has stimulated intensive interest in preparing GABA analogs, which have superior pharmaceutical properties in comparison to GABA. Accordingly, a number of GABA analogs, with considerable pharmaceutical activity have been synthesized in the art. This review includes some of the important recent patents on novel GABA analogs and some pharmaceutical compositions there of.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18221197     DOI: 10.2174/157488906775245291

Source DB:  PubMed          Journal:  Recent Pat CNS Drug Discov        ISSN: 1574-8898


  3 in total

1.  In Vivo Detection of CPP-115 Target Engagement in Human Brain.

Authors:  Andrew P Prescot; Steven R Miller; Gary Ingenito; Rebekah S Huber; Douglas G Kondo; Perry F Renshaw
Journal:  Neuropsychopharmacology       Date:  2017-07-25       Impact factor: 7.853

2.  Enantiomers of 4-amino-3-fluorobutanoic acid as substrates for gamma-aminobutyric acid aminotransferase. Conformational probes for GABA binding.

Authors:  Michael D Clift; Haitao Ji; Gildas P Deniau; David O'Hagan; Richard B Silverman
Journal:  Biochemistry       Date:  2007-11-08       Impact factor: 3.162

3.  Neurostimulation stabilizes spiking neural networks by disrupting seizure-like oscillatory transitions.

Authors:  Scott Rich; Axel Hutt; Frances K Skinner; Taufik A Valiante; Jérémie Lefebvre
Journal:  Sci Rep       Date:  2020-09-21       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.